Indication
Anorexia
26 clinical trials
32 products
2 drugs
Clinical trial
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyStatus: Recruiting, Estimated PCD: 2024-05-01
Product
PsilocybinProduct
ponsegromabClinical trial
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)Status: Active (not recruiting), Estimated PCD: 2024-03-13
Product
PlaceboProduct
PF-06946860 PlaceboClinical trial
A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF-06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA, FOLLOWED BY AN 18-WEEK OPEN-LABEL TREATMENT PERIODStatus: Completed, Estimated PCD: 2022-04-14
Product
PF-06946860Product
PonsegromabProduct
Ketamine HclClinical trial
Case Series: A Sequenced Treatment Using a Modified Ketogenic Diet and Ketamine for Severe and Enduring Anorexia NervosaStatus: Completed, Estimated PCD: 2022-07-26
Clinical trial
A Double-Blind Placebo-Controlled Evaluation of Effectiveness of Oral Naltrexone in Management of Adolescent Eating DisordersStatus: Terminated, Estimated PCD: 2024-05-21
Product
NaltrexoneClinical trial
Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot StudyStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
RomosozumabProduct
AlendronateClinical trial
Qualitative Study on Experiences Related to Anorexia and the Effects of Anamorelin and Placebo in Advanced Non-Small-Cell Lung Cancer Patients With Anorexia-Cachexia: A Preliminary StudyStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
AnamorelinClinical trial
The Role of Cannabidiol in Regulating Meal Time Anxiety in Anorexia Nervous: Safety, Tolerability and PharmacokineticsStatus: Recruiting, Estimated PCD: 2024-10-01
Product
CannabidiolClinical trial
The Effect of Medical Cannabis Inpatients With Palliative Pancreatic CancerStatus: Withdrawn, Estimated PCD: 2018-05-06
Product
THC and CBD MixtureClinical trial
Preliminary Study to Explore the Effects of Mirtazapine on Appetite in Advanced Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Product
MirtazapineClinical trial
Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents With Eating DisordersStatus: Recruiting, Estimated PCD: 2026-09-01
Drug
VarlilumabClinical trial
Study of Translational Process of Relationship Between Intestinal Microbiota of Dysbiosis and the Psychic Symptoms of Anorexia Nervosa (Eating Disorders and Anxio-depression Disorders)Status: Recruiting, Estimated PCD: 2025-07-01
Product
Stool and blood samplesClinical trial
Metreleptin in Anorexia Nervosa, Randomized Controlled Trial; Effects on Depressive Symptoms and Concomitant Changes in Brain ConnectivityStatus: Not yet recruiting, Estimated PCD: 2026-02-01
Product
MetreleptinProduct
Sodium chlorideClinical trial
Study of Psilocybin for Anorexia in Young AdultsStatus: Not yet recruiting, Estimated PCD: 2029-06-01
Clinical trial
Multimodal Longitudinal and Machine Learning-based Predictive Modelling to Understand the Development of Eating DisordersStatus: Recruiting, Estimated PCD: 2024-12-01
Product
Blood and urine samplesClinical trial
Feasibility Study of Using Fecal Microbiota Transplants (FMT) in Supportive Treatment of Anorexia NervosaStatus: Recruiting, Estimated PCD: 2025-11-01
Product
Fecal Microbiome TransplantClinical trial
Toward Understanding Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia NervosaStatus: Active (not recruiting), Estimated PCD: 2023-09-06
Product
amisulprideProduct
bromocriptineClinical trial
Potential Predictive Biological Markers of Major Depression Response to Citalopram Therapy in Patients With Anorexia Nervosa: a Single-center Study.Status: Recruiting, Estimated PCD: 2024-08-01
Product
CitalopramClinical trial
Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.Status: Completed, Estimated PCD: 2022-02-02
Product
MegestrolClinical trial
Psilocybin as a Treatment for Anorexia Nervosa: A Pilot StudyStatus: Active (not recruiting), Estimated PCD: 2023-06-01
Clinical trial
Analgesic and Appetite-stimulating Effects of Cannabigerol Administered Alone and in Combination With Delta-9-tetrahydrocannabinolStatus: Recruiting, Estimated PCD: 2024-12-22
Product
Low CBGProduct
High CBGProduct
Low THCProduct
THCClinical trial
Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Severe and Enduring Anorexia Nervosa (SE-AN)Status: Withdrawn, Estimated PCD: 2024-03-01
Clinical trial
Effectiveness of Cannabinoid on Appetite, Sleep Quality, Quality of Life, Joint Pain, and Cytokine Level in Systemic Sclerosis Patients: a Randomized Placebo-controlled TrialStatus: Recruiting, Estimated PCD: 2024-12-01
Product
CBD oilClinical trial
Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia NervosaStatus: Recruiting, Estimated PCD: 2025-09-30
Product
Transdermal estrogenProduct
PlacebosClinical trial
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated AnorexiaStatus: Recruiting, Estimated PCD: 2026-05-01
Drug
OlanzapineProduct
Megestrol Acetate